Financials
- Market Capitalization 1.79 B
- Employee 110
- Founded 2024
- CEO N/A
- Website www.inhibrx.com
- Headquarter Delaware, United States
- FIGI BBG01MS5Q9G3
- Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-10.67
ratio cours/chiffre d'affaires
—
Related tickers
| # | Nom | Prix | 24h % | 7 jours % | 1M % | 1 an % | Cap Boursière | 7 Derniers Jours | |
|---|---|---|---|---|---|---|---|---|---|
| 2041 | TSHA Taysha Gene Therapies, Inc. - Common Stock | 5.75 USD | +1.05% | -8.15% | -2.38% | +98.28% | 1.87 B USD | ||
| 2064 | RXRX Recursion Pharmaceuticals, Inc. - Class A Common Stock | 3.34 USD | -1.76% | -6.18% | +10.23% | -27.23% | 1.79 B USD | ||
| 2070 | SEPN Septerna, Inc. - Common Stock | 37.86 USD | -0.76% | -6.66% | +9.90% | +72.01% | 1.77 B USD | ||
| 2075 | NTLA Intellia Therapeutics, Inc. - Common Stock | 12.74 USD | +0.08% | -6.60% | +20.30% | -7.14% | 1.79 B USD |